Wave Life Sciences stock trades at EUR 3.27: Q3 revenue reaches USD 13.16 million

Published on 10/29/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The November 4, 2026 Research Day adds a dated catalyst for Wave Life Sciences stock, while cash totaled USD 431 million at quarter-end.

Cash and pipeline dates

Wave Life Sciences reported a third-quarter net loss of USD 61.91 million on October 27, 2026.
Research and development spending reached USD 53.80 million in the third quarter of 2026.
Wave scheduled its virtual Research Day for November 4, 2026.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) reported third-quarter 2026 revenue of USD 13.16 million, while its net loss reached USD 61.91 million. MarketBeat said the revenue figure exceeded the USD 4.51 million consensus estimate on October 27, 2026.

Three milestones shape the story

On October 15, 2026, MarketScreener reported that UBS began coverage with a Buy rating and a USD 11.00 price target. On October 20, 2026, Wave scheduled its Research Day for November 4, 2026, according to the company investor-relations page.

On October 27, 2026, the company reported third-quarter revenue of USD 13.16 million and a net loss of USD 61.91 million. The latest result therefore combines sharply higher collaboration revenue with continued clinical-development spending.

What does spending mean for the pipeline?

Research and development expense was USD 53.80 million in the third quarter of 2026, compared with USD 45.90 million in the prior-year quarter. General and administrative expense was USD 25.40 million, versus USD 18.10 million a year earlier, according to Yahoo Finance.

Research Day sets the next date

Wave's investor-relations page lists the virtual Research Day for November 4, 2026, with attention on WVE-006, WVE-007 and WVE-008. The same page identifies the third-quarter earnings call as an October 27, 2026 event and describes the company as focused on RNA medicines.

Stock trades near its yearly low

Wave Life Sciences stood at EUR 3.27 at Lang & Schwarz on October 29, 2026 at 2:10 p.m. CEST. The quote is below the USD 3.04 to USD 21.73 52-week range only in a separate home-market currency context, so no cross-currency distance is calculated. The Nasdaq-listed company had a market capitalization of USD 717.90 million on October 28, 2026, while cash, cash equivalents and marketable securities totaled USD 431 million at September 30, 2026.